Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. As-013
2. Butyryl Prostaglandin F1 Butyl Ester
3. Circulase
4. Lipo As-013
1. Circulase
2. As-013
3. 136892-64-3
4. Q2xm6vr8do
5. Butyl (4r,5r)-2,4-dihydroxy-5-((1e,3s)-3-hydroxy-1-octenyl)-1-cyclopentene-1-heptanoate, 2-butyrate
6. Ecraprost [usan:inn]
7. Unii-q2xm6vr8do
8. Lipo-pro-prostaglandin E1
9. Ecraprost [usan]
10. As 013
11. Ecraprost [inn]
12. Ecraprost (usan/inn)
13. Lipo As-013
14. Schembl4974845
15. Chembl2104574
16. Butyryl Prostaglandin F1 Butyl Ester
17. Butyl 7-[(4r,5r)-2-butanoyloxy-4-hydroxy-5-[(e,3s)-3-hydroxyoct-1-enyl]cyclopenten-1-yl]heptanoate
18. D02723
19. Q27286929
20. Butyl 7-((4r,5r)-2-(butyryloxy)-4-hydroxy-5-((s,e)-3-hydroxyoct-1-en-1-yl)cyclopent-1-en-1-yl)heptanoate
21. Prosta-8,13-dien-1-oic Acid, 11,15-dihydroxy-9-(1-oxobutoxy)-, Butyl Ester, (11 Alpha, 13e,15s)-
22. Prosta-8,13-dien-1-oic Acid, 11,15-dihydroxy-9-(1-oxobutoxy)-, Butyl Ester, (11.alpha.,13e,15s)-
23. Prosta-8,13-dien-1-oic Acid, 11,15-dihydroxy-9-(1-oxobutoxy)-, Butyl Ester, (11alpha,13e,15s)-
| Molecular Weight | 480.7 g/mol |
|---|---|
| Molecular Formula | C28H48O6 |
| XLogP3 | 5.9 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 21 |
| Exact Mass | 480.34508925 g/mol |
| Monoisotopic Mass | 480.34508925 g/mol |
| Topological Polar Surface Area | 93.1 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 639 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Ecraprost manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ecraprost, including repackagers and relabelers. The FDA regulates Ecraprost manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ecraprost API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ecraprost supplier is an individual or a company that provides Ecraprost active pharmaceutical ingredient (API) or Ecraprost finished formulations upon request. The Ecraprost suppliers may include Ecraprost API manufacturers, exporters, distributors and traders.
Ecraprost Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ecraprost GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ecraprost GMP manufacturer or Ecraprost GMP API supplier for your needs.
A Ecraprost CoA (Certificate of Analysis) is a formal document that attests to Ecraprost's compliance with Ecraprost specifications and serves as a tool for batch-level quality control.
Ecraprost CoA mostly includes findings from lab analyses of a specific batch. For each Ecraprost CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ecraprost may be tested according to a variety of international standards, such as European Pharmacopoeia (Ecraprost EP), Ecraprost JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ecraprost USP).
LOOKING FOR A SUPPLIER?
